Policy & Regulation
TrippBio to evaluate the efficacy of TD213 in confirmed COVID-19 infections in Proof of Concept clinical trial
23 October 2020 -

Biotechnology company TrippBio said on Thursday that it plans to develop a groundbreaking patent-pending repurposed USD FDA approved drug called TD213 for viral infections caused by COVID-19.

The company said TD213 works by blocking the SARS-CoV-2 virus' replication and the associated acute inflammatory response to the infection.

Additioanally, Dr Moti N Ramgopal of Midway Immunology and Research Center launched the investigator-initiated study (IIS) to assess the efficacy of the company's TD213 in treating patients with confirmed mild - moderate COVD-19 infections. The final patient was enrolled in this proof of concept (POC) study and all participants are progressing through the protocol designated testing and follow-up visits.

In conjunction, the company seeks support of the worldwide community to continue into the next phase of testing and will use the capital from ongoing equity crowdfunding to extend clinical trials needed for the global regulatory approval and commercialization of TD213.



Related Headlines